



IN VITRO EVALUATION OF ANTIFUNGAL POTENTIAL AND ELECTRON MICROSCOPIC STUDIES 
OF BACILLUS AMYLOLIQUEFACIENS AGAINST ASPERGILLUS SPECIES 
Original Article 
 
ANU SINGH, MEENAKSHI BALHARA, BHARAT SINGH, ANIL KUMAR CHHILLAR
Centre for Biotechnology, Maharshi Dayanand University, Rohtak, Haryana, India
* 
 
 Received: 16 Mar 2015 Revised and Accepted: 30 May 2015 
Email: anil.chhillar@gmail.com   
ABSTRACT 
Objective: Bacteria are able to synthesize a wide range of metabolites with fungicidal properties. The present study focused on the in vitro 
evaluation of antifungal potential of amyloliquefaciens DSM-1067 against Aspergillus spp. and its electron microscopic studies.  
Methods: An invitro evaluation of antifungal activity of bacterial secreted and cellular proteins was determined by microbroth dilution, disc 
diffusion and spore germination inhibition assays (SGIA). The cytotoxicity of these bacterial proteins was determined by hemolytic assay, and the 
effect of Bacillus amyloliquefaciens DSM 1067 lysate proteins on Aspergillus fumigatus was visualized by scanning electron microscopy (SEM). 
Results: Bacillus amyloliquefaciens DSM-1067 lysates showed the highest activity by inhibiting the growth of A. fumigatus, A. flavus completely at a 
concentration of 31.25 µg/ml. In vitro toxicity experiments resulted that the lysate of B. amyloliquefaciens DSM-1067was non-toxic against human 
erythrocytes even at high concentrations. These findings thus emphasize its usefulness in the development of new antifungal therapies. SEM 
analysis demonstrated the in vitro inhibition of A. fumigatus growth by B. amyloliquefaciens DSM-1067cytosolic proteins leading to wrinkled 
hyphae, irregular branching patterns. It also showed disruption of conidiophores development. These cytological effects of B. amyloliquefaciens 
DSM-1067on the hyphal growth of A. fumigatus can explain its potent anti-Aspergillus activity. 
Conclusion: The present investigation revealed that B. amyloliquefaciens DSM-1067 lysate protein can act as a potential candidate for exploration in 
the development of effective and non-toxic treatments against Aspergillus induced diseases. Its effect on the development of conidiophores and 
hyphal growth are studied in the present study.  
Keywords: Anti-Aspergillus, Bacillus amyloliquefaciens, Toxicity, Aspergillus species, Scanning electron microscopy. 
 
INTRODUCTION 
The incidence of systemic mycoses caused by filamentous fungi has risen 
significantly in the last decades mainly due to the increased use of 
immunosuppressive therapy [1]. Exposure to Aspergillusspecies may 
cause allergic reactions in hyper-sensitized hosts and/or invasive 
infections in highly immunosuppressed individuals [2]. Among the 
human pathogenic species of Aspergillus: A. fumigatus is the primary 
causative agent of induced infections, followed by A. flavus, A. terreus, A. 
niger, and A. nidulans [3]. Reports have shown that the organ transplant 
patients suffering from invasive aspergillosis (IA) are predominant and a 
serious matter of concern [4, 5]. Also limitations of currently available 
antifungal agents are associated with high toxicity, complex drug 
interactions and limited efficacy showing mortality rates up to 60-90% 
[6]. The employment of natural bio resources for treating invasive fungal 
infections has been focused in the recent decades [7-9]. It has been 
reported that the Serratiamarcescens exhibited strong in vitro antifungal 
activity against pathogenic fungi including Aspergillus species [10]. In 
another report B. amyloliquefaciens produces a "broad-spectrum" 
antifungal proteins, among them baciamin was the one which showed 
potent antifungal activity [11]. Several strains of B. subtilis and B. 
amyloliquefacien shave been reported to produce lipopeptides displaying 
strong antifungal activity with low toxicity, high biodegradability [12]. 
The B. amyloliquefaciens strain "TF-28" was reported as a particular 
endophytic bio control strain which showed an effective inhibitory effect 
on F. moniliforme [13]. There is a series of bacteria which are rarely 
reported for having significant properties and clinical utility (including 
treatment of IA) with no mechanism of action. In view of this, the present 
investigation was undertaken to explore the anti-Aspergillus properties 
of bacterial isolates for their future use to develop novel antifungal 
therapies. 
MATERIALS AND METHODS 
Bacterial strains 
Bacillus amylo liquefaciens DSM-1067(MTCC 2248), Serratia 
marcescens (MTCC 9527), Streptomyces noursei (MTCC 6210), 
Streptococcus mutans (MTCC 890), E. coli (MTCC 1671), Staphylococcus 
aureus (MTCC 3160), Bacillus cereus (MTCC 10085), Bacillus subtilis 
(MTCC1133), Bacillus subtilis (MTCC1483), Streptomyces spp.. (MTCC 
4066), Micrococcus luteus (MTCC 8132) were purchased from an 
Institute of Microbial Technology, Chandigarh, India. These strains 
were cultured in Luria Broth (LB) for 3 days at 37 °C in an incubator 
shaker. The cells were counted by the turbidometry method and used 
for performing various experiments. 
Pathogens 
Clinical isolates of Aspergillus spp. obtained from Indian Agriculture 
Research Institute, New Delhi, India were employed in the current study. 
Three pathogenic species of Aspergillus spp. namely A. fumigatus, A. 
flavus and A. nigerwere cultured in laboratory on Sabouraud dextrose 
agar plates. The plates were inoculated with stock cultures of A. 
fumigatus, A. flavus and A. niger and incubated in a BOD incubator 
(Hicon, India) at 37 °C. The spores were harvested from 96 h cultures 
and suspended homogeneously in phosphate buffer saline (PBS), pH 7.4 
in a test tube. A homogeneous spore suspension was obtained by 
incubating the tube at 37 °C for 60 min with intermittent shaking. The 
spores in the suspension were counted and their number was adjusted 
to 1 x 108
Preparation of bacterial supernatant and lysate 
 spores/ml before performing the experiments. 
The 72 h log phase cultures of bacterial strains were centrifuged at 
3256 g for 30 min in Sigma refrigerated centrifuge. The supernatant 
was collected in a flask for testing the antifungal activity and pellet 
was washed with PBS thrice and suspended in sonication buffer (50 
mmol/l Tris-HCl, 50 mmol/l Ethylenediaminetetraacetic acid, 5 
mmol/l 5 mmol/l Dithiothreitol, 1 mmol/l Phenyl methane sulfonyl 
fluoride). The cell suspension was sonicated by following the 
program: 20 s bursts at 200 W and 10 s cool periods (2 min) using a 
sonicator. The sonicated material was centrifuged at 16350 g for 30 
min using Sigma refrigerated centrifuge. The supernatant was 
collected and used as lysate. The lysate was dialysed against distilled 
water at 4 °C for 24 h with several changes of water and lyophilized. 
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Protein concentration of bacterial supernatant and lysate was 
determined by BCA method [14]. 
Antifungal activity 
The antifungal activity of bacterial components was analysed by 
micro broth dilution assay (MDA), disc diffusion assay (DDA) and 
spore germination inhibition assay (SGIA) as described earlier [15]. 
Each experiment was repeated at least three times. 
Microbroth dilution assay 
The test was performed in 96-well culture plates (Tarsons, Kolkata, 
India). Autoclaved Sabouraud dextrose broth (90 µl) was added to 
the wells of culture plates. Various concentrations of bacterial 
proteins in the range of 1000.0 to3.9 µg/ml) were prepared in the 
wells by two-fold dilution method and these wells were inoculated 
with 10 µl of spore suspension containing 1 x 106
The wells were prepared in duplicates for each concentration. The 
wells were inoculated with 10 µl of spore suspension containing 
100±5 spores. Appropriate control wells treated with Amphotericin 
B or without any treatment were included in the study. The plates 
were incubated at 37 °C for 16 h and then examined for spore 
germination under the compound microscope (Labomed, USA). The 
number of germinated and non-germinated spores was counted and 
the percent spore germination inhibition (PSGI) was calculated 
using following formula:  
 spores. The plates 
were incubated at 37 °C and examined macroscopically after 48 h for 
the growth of Aspergillus mycelia. Appropriate control wells treated 
with Amphotericin B or without any treatment were included in the 
study. A protein was considered to be active if the wells appeared 
clear without any visible growth of Aspergillus and the results were 
expressed as minimum inhibitory concentration (MIC). 
Disc diffusion assay 
The disc diffusion test was performed in radiation sterilized Petri 
plates of 10.0 cm diameter. Different concentrations ranging from 
50.00 to 3.20 µg of proteins/disc of the bacterial extracts were 
impregnated on the sterilized discs (5.0 mm in diameter) of What 
man filter paper No. 1. These discs were placed on the surface of the 
agar plates, which were already inoculated with Aspergillus spores. 
The plates were incubated at 37 °C and examined after 48 h for zone 
of inhibition, if any, around the discs. The diameter of zone of 
inhibition was recorded. The concentration, which developed the 
zone of inhibition of at least 6.0 mm diameter, was considered as 
MIC. Amphotericin B was used in assay as a standard control drug. 
An additional control disc without any sample but impregnated with 
equivalent amount of solvent was also used in the assay. 
Spore germination inhibition assay 
The Aspergillus species were grown on Sabouraud dextrose agar 
plates and their homogenous spore suspension was prepared in the 
Sabouraud dextrose broth. Various concentrations (1000 to 3.9 
µg/ml) of the bacterial proteins in 90 µl of culture medium were 
prepared in 96-well flat bottom micro culture plates (Tarsons, 
Kolkata, India) by double dilution method.  
PSGI = (100-No. of spores germinated in drug treated well/No. of 
spores germinated in control well) x 100 
The activity of the preparations was represented as the MIC90
Haemolytic assay 
 which 
inhibits the germination of spores in the range of 90-100%. 
The basic method of Latoud et al., 1986 [16] with slight modifications 
was employed to determine the hemolytic effect of bacterial proteins on 
mammalian cells. Human erythrocytes, collected from apparently 
healthy individuals, were washed three times with PBS by centrifugation 
at 1500 revolutions per min (rpm) for 10 min. A 2% erythrocyte 
suspension was incubated at 37 ºC for 1 h with different concentrations 
of protein lysate ranging from 1000.0 to 15.60 µg/ml. After incubation, 
cells were pelleted at 5000 rpm for 10 min in refrigerated centrifuge 
(Sigma, Germany). The supernatant was collected and the Absorbance at 
450 was determined using a spectrophotometer (UV Vis Spect Lambda 
Bio 20; Perkin Elmer). In negative control sets, only buffer was used for 
background lysis, whereas in positive controls, lysis buffer was used for 
completely lysing the erythrocytes. For each sample, the percentage of 
maximum haemolytic activity was determined. 
Scanning electron microscopy 
The A. fumigatus was cultured in 100 ml of L-asparagine broth using 
a spore suspension of 1 x 106spores/ml for 24 h in a BOD incubator 
shaker at 37 oC, 100 rpm and treatment with MIC50 of B. 
amyloliquefaciens DSM-1067 protein to examine its effect on fungus 
morphology and spore germination along with control untreated 
cultures. Fungal mass recovered from culture and used for SEM 
studies. The cells were fixed with 2.5% glutaraldehyde in 0.1 mol/l 
phosphate buffer (pH 7.2) at 48 o
The secreted and cellular proteins (lysate) of B. amyloliquefaciens DSM-
1067, S. marcescens, S. noursei, S. mutans, E. coli,S. aureus, B. cereus, B. 
subtilis, Streptomyces spp. and M. Luteus were prepared.  
C for 2h. All specimens were washed 
four times with phosphate buffer and post-fixed with phosphate 
buffered 2% osmium tetroxide at 48 °C for 4 h. After washing overnight 
with the same buffer, the specimens were dehydrated in graded ethanol 
and finally freeze-dried in t-butyl alcohol. The specimens were coated 
with gold film (approximately 10 nm). Samples were examined using a 
Carl Zeiss EV040 Gemini field emission scanning microscope with an 
acceleration voltage of 20 kv using the Everhart Thornley SE detector 
and the in-lens SE detector in a 50:50 ratio. 
RESULTS 
 
Table 1: Antifungal activity of secreted proteins of bacterial strains evaluated by microbroth dilution assay against pathogenic fungi (A. 
fumigatus, A. flavus and A. niger) 
Bacteria evaluated for antifungal activity MIC90 of Bacterial secreted proteins (µg/ml) 
MTCC No. Bacterial species A. fumigatus A. flavus A. niger 
1482 Bacillus amyloliquefaciens 125 125 250 
9527  Serratia marcescens 125 250 250 
1577  Escherichia coli  62.5 62.5 125 
6210 Streptomyces noursei 125 125 125 
2248  Bacillus amyloliquefaciens DSM-1067 125 125 250 
3160  Staphylococcus aureus 31.2 31.2 62.5 
10085  Bacillus cereus  15.6 15.6 31.5 
8601 Bacillus subtilis - - 250 
8142  Bacillus subtilis - - - 
890  Streptococcus mutans 250 250 - 
1671 Escherichia coli  125 250 - 
8132  Micrococcus luteus 250 250 500 
4066  Streptomyces spp. 250 125 250 
1302  Escherichia coli  62.5 62.5 250 
8848  Bacillus amyloliquefaciens 62.5 62.5 125 
10439  Bacillus amyloliquefaciens 125 125 250 
Drug 
[Total =16] 
Amphotericin B 1.25 1.25 2.50 
*Protein extracts of 16 bacterial isolates. MIC: minimum inhibitory concentration, MIC reported are the mean value of triplicates. 
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Table 2: Antifungal activity of lysate proteins of different bacterial strains evaluated by microbroth dilution assay against pathogenic 
fungi (A. fumigatus, A. flavus and A. niger) 
Bacteria evaluated for antifungal activity MIC90 of Bacterial secreted proteins(µg/ml) 
MTCC No. Bacterial Species A. fumigatus A. flavus A. niger 
1482 Bacillus amyloliquefaciens 62.50 62.50 31.20 
9527  Serratia marcescens 62.50 62.50 125 
1577  Escherichia coli  62.50 62.50 250 
6210 Streptomyces noursei 62.50 62.50 31.25 
2248  Bacillus amyloliquefaciens DSM-1067 31.2 31.25 62.50 
3160  Staphylococcus aureus 125 125 62.50 
10085  Bacillus cereus  15.6 15.6 62.50 
8601 Bacillus subtilis - - - 
8142  Bacillus subtilis - - - 
890  Streptococcus mutans 250 250 500 
1671 Escherichia coli  500 250 - 
8132  Micrococcus luteus 250 250 500 
4066  Streptomyces spp. 500 250 125 
1302  Escherichia coli  250 - - 
8848  Bacillus amyloliquefaciens 250 125 125 
10439  Bacillus amyloliquefaciens 125 125 250 
Drug [Total =16] Amphotericin B 1.25 1.25 2.50 
*Protein extracts of 16 bacterial isolates. MIC: minimum inhibitory concentration. MIC reported are the mean value of triplicates. 
 
 
Fig. 1: Graph showing the growth inhibition of Aspergillus 
species by lysate proteins of Bacillus amyloliquefaciens DSM-
1067, demonstrated through percent spore germination assay 
*Aspergillusfumigatus (A. fumigatus), Aspergillusflavus (A. 
flavus) and Aspergillusniger (A. niger) 
The antifungal activity of secreted and cellular proteins of these 
bacterial strains was evaluated by MDA in comparison of positive 
standard drug Amphotericin B. The lysates were showed mild to 
moderate activity against Aspergillus species as represented in 
table 1 and 2. 
The secreted proteins of B. amyloliquefaciens, S. marcescens, S. 
noursei, E. coli, S. aureus and B. cereus depicted significant 
antifungal activity against Aspergillus isolates having a MIC in 
the range between 125 µg/ml to 15.6 µg/ml. Out of them B. 
cereus showing the highest activity against A. fumigatus. 
Similarly cellular lysate proteins of B. amyloliquefaciens DSM-
1067 and S. marcescens showed the MIC at31.25 µg/ml and 62.50 
µg/ml having the highest activity against A. fumigatus and A. 
flavus in MDA and PSGI (fig. 1) and showing MIC at 62.50 µg/ml 
and125 µg/ml against A. niger. 
The DDA experimental results in table 3 and 4 demonstrated the 
lowest concentration of B. Amyloliquefaciens DSM-1067 lysate 
proteins was 6.20 µg/disc which showed significant activity against 
of A. fumigatus, while it was 12.5 µg/disc in case of S. marcescens. 
  
Table 3: Antifungal activity of lysate proteins of Bacillus amyloliquefaciens DSM-1067 and Serratia marscecens against Aspergillus spp. 
demonstrated by disc diffusion method 
Zone of inhibition (mm) 
A. fumigatus A. flavus A. niger 
mean±SD CV mean±SD CV mean±SD CV 
Bacillus amyloliquefaciens DSM-1067 
Lysate proteins concentrations (µg/disc.) 
50 11.0±0.10 0.010 11.00±0.10 0.010 10.80±0.3 2.60 
25 10.90±0.20 0.060 10.90±0.10 0.020 10.03±0.15 0.023 
12 9.03±0.05 0.003 9.03±0.05 0.003 6.50±0.10 0.010 

















50 10.50±0.10 0.010 10.70±0.05 0.003 8.90±0.10 0.010 
25 9.20±0.20 0.040 9.10±0.10 0.010 6.50±0.05 0.0 
12 6.10±0.15 0.020 6.06±0.05 0.003 0.0 0.0 
6.20 0.0 0.0 0.0 0.0 0.0 0.0 
3.10 0.0 0.0 0.0 0.0 0.0 0.0 
*CV: Coefficient of variance, Amp B: Amphotericin B 
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Table 4: Minimum inhibitory concentrations (MICs) of lysate proteins of Bacillus amyloliquefaciens DSM-1067 and Serratia marcescens 
against Aspergillus spp., evaluated by various antifungal susceptibility tests 
Pathogen * MIC of Bacillus amyloliquefaciens DSM-1067 (µg/ml) MIC of Serratia marcescens (µg/ml) 



























125.00 125.00 25.00 
*MIC reported are the mean value of triplicates, Amp B: Amphotericin B (Standard drug) 
 
The toxicity studies of the lysate proteins of all bacterial strains were 
evaluated against human erythrocytes. Among them B. 
amyloliquefaciens DSM-1067and S. marcescens lysates were found to 
be nontoxic up to the concentration of 250.0 µg/ml (i.e. cell lysis less 
than 5%) which were significant as compared to standard drug 
Amphotericin B i.e. 100% lysis at a concentration of 37.5 µg/ml (fig. 2).  
 
 
*Amphotericin B (AmpB) B. amyloliquefaciens DSM-1067 (B. 
amylo) and S. marcescens(S. marceses) 
Fig. 2: Graph showing hemolytic activity of bacterial lysate proteins 
in comparison to standard drug using human erythrocytes 
 
The SEM analysis revealed that the control sample (without any 
treatment) showed typical conidial morphology of A. fumigatus 
where fungal hyphae were long-single stranded, stretched, elongated 
and highly dense with interconnected conidiophores (fig. 3a). Whereas 
severe defects on fungal hyphal growth, structure and conidial 
morphology were examined through SEM analysis when A. 
fumigatusconidia (1 x 106spores/ml) were treated with cellular 
proteins of B. Amyloliquefaciens DSM-1067 (MIC50
 
) as shown in fig. 3b.  
 
Fig. 3: Scanning electron microscopy images of Aspergillus 
fumigatus untreated sample 
(a) hyphae are long, straight with smooth surfaces and 
branched conidiophores, whereas in bacterial lysate protein 
treated sample of Aspergillus fumigatus (b) hyphae are short, 
irregular along with shrinking of hyphal walls and damage 




In the present study crude lysate proteins of B. amyloliquefaciens 
DSM-1067and S. marcescens showed significant antifungal activity 
against pathogenic species of Aspergillus. Although the MIC of active 
fractions is in the range of 30-60 µg/ml which is less as compared to 
standard drugs, but they are 10-25 fold less toxic than standard to 
compensate the higher doses. The MIC of B. amyloliquefaciens DSM-
1067 as compared to the S. marcescens is lower, determined by MDA, 
DDA and PSGI and also less toxic. The products of B. 
amyloliquefaciens have been reported to be used as a biocontrol 
agent with antifungal activity [17]. Such properties of B. 
amyloliquefaciens DSM-1067 may be due to biologically active 
proteins, as indicated in present investigation. Moderate type of 
activity was observed in case of S. noursei. The lysate exhibited 
better activity than the supernatant (supernatant MIC 125µg/ml and 
lysate MIC 62.50 µg/ml). The antifungal properties of Streptomyces 
supernatant containing secretory proteins are reported with an 
appreciable level of activity in supernatant; however, observers did 
not evaluate the anti-Aspergillus properties of Streptomyces lysates 
[12]. The lysates and supernatants of S. mutans, Micrococcus luteus 
and B. subitis were found to be less active against A. fumigatus. The S. 
aureus supernatant exhibited better activity than the lysate and B. 
cereus having significant activity of cellular lysate against Aspergilli, 
but its cytotoxicity was quite high.  
The SEM studies revealed the effect of B. Amyloliquefaciens DSM-
1067 treatment which demonstrated inhibition of A. fumigatus 
growth, affected hyphal morphology with shrunken hyphal walls, 
disruption of both hyphal tips and conidiophores and ultimately led 
to the destruction of whole hyphae. Findings of the present study 
revealed that the B. amyloliquefaciens DSM-1067 had significant 
activity against Aspergilli and it found to be good/eco-friendly 
bacterium. It can further be used as probiotic "which are having 
potent candidate with therapeutic value" against Aspergilli and its 
nontoxic behavior may discover potential bioactive molecules for 
treating Aspergillus-induced diseases.  
CONCLUSION 
A group bacterial strain was screened for anti-Aspergillus activity 
against pathogenic clinical isolates of Aspergillus species. The lysate 
protein of B. amyloliquefaciens DSM-1067 showed the highest anti-
Aspergillus activity having MIC (31.2 µg/ml) and its morphological 
changes of hyphae lateral walls, disruption of the hyphal tips and 
branches, abrupt conidiophores germination as well as demolishing 
of whole hyphal structure. Less toxicity against human cells shows 
that it may be used as the source of bioactive protein(s) which might 
have be utilized as therapeutic agents against aspergillosis because 
various strains of Bacillus are already used as the potential source of 
probiotics. 
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